BMJ  2005;331:723 (1 October), doi:10.1136/bmj.331.7519.723

Paper

Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial

Lars Høj, staff specialist1, Placido Cardoso, researcher2, Birgitte Bruun Nielsen, staff specialist1, Lone Hvidman, consultant obstetrician1, Jens Nielsen, statistician3, Peter Aaby, professor3

1 Department of Obstetrics and Gynaecology, Aarhus University Hospital, 8200 Aarhus N, Denmark, 2 Projecto de Saúde de Bandim, Apartado 861, Bissau, Guinea-Bissau, 3 Bandim Health Project, Danish Epidemiology Science Centre, Statens Serum Institut, 2300 Copenhagen S, Denmark

Correspondence to: L Høj lars.hoj{at}dadlnet.dk

Objective To evaluate whether routine administration of sublingual misoprostol 600 µg after delivery reduces postpartum haemorrhage.

Design Randomised double blind placebo controlled trial.

Setting Primary health centre in Bissau, Guinea-Bissau, West Africa.

Participants 661 women undergoing vaginal delivery.

Intervention Misoprostol 600 µg or placebo administered sublingually immediately after delivery.

Main outcome measures Postpartum haemorrhage, defined as a loss of ≥ 500 ml and decrease in haemoglobin concentration after delivery.

Results The incidence of postpartum haemorrhage was not significantly different between the two groups, the relative risk being 0.89 (95% confidence interval 0.76 to 1.04) in the misoprostol group compared with the placebo group. Mean blood loss was 10.5% (-0.5% to 20.4%) lower in the misoprostol group than in the control group. Severe postpartum haemorrhage of ≥ 1000 ml or ≥ 1500 ml occurred in 17% (56) and 8% (25) in the placebo group and 11% (37) and 2% (7) in the misoprostol group. Significantly fewer women in the misoprostol group experienced a loss of ≥ 1000 ml (0.66, 0.45 to 0.98) or ≥ 1500 ml (0.28, 0.12 to 0.64). The decrease in haemoglobin concentration tended to be less in the misoprostol group, the mean difference between the two groups being 0.16 mmol/l (-0.01 mmol/l to 0.32 mmol/l).

Conclusion Sublingual misoprostol reduces the frequency of severe postpartum haemorrhage.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Misoprostol helps anaemic women in childbirth
BMJ 2005 331: 0. [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Inadequate reporting of safety issues from clinical trials in academic journals
Susan C Morgan
bmj.com, 14 Oct 2005 [Full text]
Misoprostol: An essential drug to save mothers' lives
Godfrey Mbaruku, et al.
bmj.com, 18 Oct 2005 [Full text]
Re: Inadequate reporting of safety issues from clinical trials in academic journals
Lars Høj
bmj.com, 19 Oct 2005 [Full text]
Figure error?
Andrew D Weeks
bmj.com, 21 Oct 2005 [Full text]
Questions for authors regarding the effect of sublingual misoprostol on postpartum haemorrhage
Nancy L. Sloan, et al.
bmj.com, 4 Nov 2005 [Full text]
Was active management of the third stage of labor used in the research study?
Deborah A. Armbruster
bmj.com, 12 Nov 2005 [Full text]
Misoprostol in the third stage of labour and maternal mortality: a review
A. Metin Gülmezoglu, et al.
bmj.com, 4 Jan 2006 [Full text]



Access jobs at BMJ Careers
Whats new online at Student 

BMJ